trending Market Intelligence /marketintelligence/en/news-insights/trending/if6ioq5a7hn5bi0_wjqgyw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Xencor prices common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Xencor prices common stock offering

Xencor Inc. priced an underwritten public offering of 7,300,000 common shares at $31 each.

The company expects to raise gross proceeds of about $226.3 million through the offering, which is expected to close on or about March 23, subject to customary closing conditions.

Xencor granted underwriters a 30-day overallotment option to buy up to an additional 1,095,000 shares.

The company plans to use net proceeds for working capital and general corporate purposes.

Leerink Partners and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co., Wedbush PacGrow, Canaccord Genuity and BTIG as co-managers.

Monrovia, Calif.-based Xencor develops treatments for autoimmune diseases, asthma and allergic diseases and cancer.